What is the Sermaglutide?

Sermaglutide is , while it's Molecular Formula is C187H291N45O59. Semaglutide injection (Wegovy) is used along with an individualized low-calorie, low-fat diet and exercise program to help with weight loss in overweight adults who may also have high blood pressure, diabetes, or high cholesterol. Semaglutide injection is in a class of medications called incretin mimetics. It works by helping the pancreas to release the right amount of insulin when blood sugar levels are high. Insulin helps move sugar from the blood into other body tissues where it is used for energy. Semaglutide injection also works by slowing the movement of food through the stomach and may decrease appetite and cause weight loss.

What is the CAS number for Sermaglutide?

The CAS number of Sermaglutide is 910463-68-2.

What is Sermaglutide (910463-68-2) used for?

Semaglutide, sold under the brand name Ozempic among others, is an anti-diabetic medication used for the treatment of type 2 diabetes and chronic weight management. Semaglutide acts like human glucagon-like peptide-1 (GLP-1) such that it increases insulin secretion, thereby increasing sugar metabolism. It is distributed as a metered subcutaneous injection in a prefilled pen, or as an oral form. One of its advantages over other antidiabetic drugs is that it has a long duration of action, thus, only once-a-week injection is sufficient.

Product Class

910463-68-2

Product Name：Semaglutide
Molecular Formula：C187H291N45O59
Purity：99%
Molecular Weight：4113.57754

Inquiry

Product Details:

CasNo： 910463-68-2

Molecular Formula： C187H291N45O59

Semaglutide

Molecular Formula:C187H291N45O59
Molecular Weight:4113.57754
PSA：1646.18000
LogP:5.44520

What is the difference between Ozempic, Wegovy and Rybelus?

Brand of Semaglutide	Ozempic	Wegovy	Rybelsus
Form	subcutaneous injection	subcutaneous injection	tablet
Strength	0.25 mg or 0.5 mg dose pen, 1 mg dose pen, 2mg dose pen.	0.25 mg dose pen, 0.5 mg dose pen, 1 mg dose pen, 1.7 mg dose pen, 2.4 mg dose pen	3mg tablet, 7mg tablet, 14mg tablet
Dose	weekly	weekly	daily
Uses	Used to help control blood sugar levels in type 2 diabetic patients, it is used together with diet and exercise. It is also used to reduce the risk of major cardiac events such as heart attack and strokes in type 2 diabetic patients who already have cardiovascular disease.	Used for weight loss for patients who have an initial BMI (body mass index) of 30kg/m2 or greater or patients who have a BMI of 27kg/m2 or greater and also have least one weight-related condition, such as high blood pressure, type 2 diabetes and high cholesterol. It is use together with diet and exercise. Used to reduce the risk of heart attack, stroke, and cardiovascular death in adults who are obese or overweight and have cardiovascular disease. It is used with a reduced-calorie diet and increased physical activity.	Used to help control blood sugar levels in type 2 diabetic patients, it is used together with diet and exercise.
Ingredients	disodium phosphate dihydrate, propylene glycol, phenol, and water for injections. Ozempic has a pH of approximately 7.4. Hydrochloric acid or sodium hydroxide may be added to adjust pH.	disodium phosphate dihydrate, sodium chloride, and water for injection.	magnesium stearate, microcrystalline cellulose, povidone and salcaprozate sodium (SNAC).
Storage	Prior to first use, Ozempic should be stored in a refrigerator between 36ºF to 46ºF (2ºC to 8ºC). Do not store in the freezer or directly adjacent to the refrigerator cooling element. Do not freeze Ozempic and do not use Ozempic if it has been frozen. After first use of the Ozempic pen, the pen can be stored for 56 days at controlled room temperature (59°F to 86°F; 15°C to 30°C) or in a refrigerator (36°F to 46°F; 2°C to 8°C). Do not freeze. Keep the pen cap on when not in use. Ozempic should be protected from excessive heat and sunlight. Always remove and safely discard the needle after each injection and store the Ozempic pen without an injection needle attached. Always use a new needle for each injection.	Store the single-dose pen in the refrigerator from 2°C to 8°C (36°F to 46°F). If needed, prior to cap removal, the pen can be kept from 8°C to 30°C (46°F to 86°F) for up to 28 days. Do not freeze. Protect Wegovy from light. Wegovy must be kept in the original carton until time of administration. Discard the Wegovy pen after use.	Store at 68° to 77°F (20 to 25°C); excursions permitted to 59° to 86°F (15° to 30°C) [see USP Controlled Room Temperature]. Store and dispense in the original bottle. Store tablets in the original bottle until used to protect tablets from moisture. Store this medicine in a dry place away from moisture.

Medication Guidance of Semaglutide(Cas 910463-68-2)

General descriptions of 3 kinds of Semaglutide

Ozempic Dosing Information
Ozempic Recommended Dosage: Start Ozempic with a 0.25 mg subcutaneous injection (injection under the skin) once weekly for 4 weeks. The 0.25 mg dosage is intended for treatment initiation and is not effective for glycemic control. After 4 weeks on the 0.25 mg dosage, increase the dosage to 0.5 mg once weekly. If additional glycemic control is needed after at least 4 weeks on the 0.5 mg dosage, the dosage may be increased to 1 mg once weekly. If additional glycemic control is needed after at least 4 weeks on the 1 mg dosage, the dosage may be increased to 2 mg once weekly. The maximum recommended dosage is 2 mg once weekly. Administer Ozempic once weekly, on the same day each week, at any time of the day, with or without meals. The day of weekly administration can be changed if necessary as long as the time between two doses is at least 2 days (>48 hours). If a dose is missed, administer Ozempic as soon as possible within 5 days after the missed dose. If more than 5 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once-weekly dosing schedule.	Ozempic is available as: Ozempic injection 0.25 mg or 0.5 mg dose pen. Pen can deliver 0.25 mg or 0.5 mg doses. 2mg/1.5mL (1.34mg/mL) Each 1.5 ml pen contains 8 doses of 0.25mg or 4 doses of 0.5mg. Ozempic injection 1 mg dose pen. Pen delivers a 1mg dose. 4mg/3mL (1.34mg/mL) Each 3ml pen contains 4 doses. Ozempic injection 2mg dose pen. Pen delivers a 2mg dose. 8mg/3mL (2.68 mg/mL) Each 3ml pen contains 4 doses.
Wegovy Dosing Information
Wegovy Recommended Dosage: Initiate Wegovy with a dose of 0.25 mg injected subcutaneously once-weekly and follow the dose escalation schedule below to minimize gastrointestinal adverse reactions Week 1 to week 4: 0.25mg weekly Week 5 to week 8: 0.5mg weekly Week 9 to week 12: 1mg weekly Week 13 to week 16: 1.7mg weekly Week 17 onwards: 2.4mg weekly If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks The maintenance dose of Wegovy is 2.4 mg injected subcutaneously once-weekly. If patients do not tolerate the maintenance 2.4 mg once-weekly dose, the dose can be temporarily decreased to 1.7 mg once-weekly, for a maximum of 4 weeks. After 4 weeks, increase Wegovy to the maintenance dose of 2.4 mg once-weekly. Discontinue Wegovy if the patient cannot tolerate the 2.4 mg dose. In patients with type 2 diabetes, monitor blood glucose prior to starting Wegovy and during Wegovy treatment.	Wegovy Strengths available: Wegovy 0.25 mg pen delivers one 0.25 mg dose (0.25 mg/0.5 mL) Wegovy 0.5 mg pen delivers one 0.5 mg dose (0.5 mg / 0.5 mL) Wegovy 1 mg pen delivers one 1 mg dose (1 mg / 0.5 mL) Wegovy 1.7 mg pen delivers one 1.7 mg dose (1.7 mg / 0.75 mL) Wegovy 2.4 mg pen delivers one 2.4 mg dose (2.4 mg / 0.75 mL)
Rybelsus Dosing Information
Rybelsus Recommended Dosage: Start Rybelsus with 3 mg once daily for 30 days. The 3 mg dose is intended for treatment initiation and is not effective for glycemic control. After 30 days on the 3 mg dose, increase the dose to 7 mg once daily. Dose may be increased to 14 mg once daily if additional glycemic control is needed after at least 30 days on the 7 mg dose. Taking two 7 mg Rybelsus tablets to achieve a 14 mg dose is not recommended. If a dose is missed, the missed dose should be skipped, and the next dose should be taken the following day. Switching Patients between Ozempic and Rybelsus Patients treated with Rybelsus 14 mg daily can be transitioned to Ozempic subcutaneous injection 0.5 mg once weekly. Patients can start Ozempic the day after their last dose of Rybelsus. Patients treated with once weekly Ozempic 0.5 mg subcutaneous injection can be transitioned to Rybelsus 7 mg or 14 mg. Patients can start Rybelsus up to 7 days after their last injection of Ozempic. There is no equivalent dose of Rybelsus for Ozempic 1 mg.	Rybelsus tablets strengths are available in 3mg, 7mg, and 14mg. Take Rybelsus at least 30 minutes before the first food, beverage, or other oral medications of the day with no more than 4 ounces of plain water only. After 30 minutes of taking the tablet you may eat, drink or take other oral medicines. Swallow tablets whole. Do not split, crush, or chew tablets.

For some special cases:

missing a dose	For Rybelsus: Skip the missed dose and use your next dose at the regular time. For Ozempic: Use the medicine as soon as you can and then go back to your regular schedule. If you are more than 5 days late for the injection, skip the missed dose and return to your regular schedule. For Wegovy: Use the medicine as soon as you can and then go back to your regular schedule. If your next dose is due in less than 2 days (48 hours), skip the missed dose and return to your regular schedule. Do not use two doses of semaglutide at one time. Call your doctor if you miss more than 2 doses in a row of Wegovy. You may need to restart the medicine at a lower dose to avoid stomach problems.
overdose	Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. Overdose may cause severe nausea, vomiting, or low blood sugar.
interactions with other drugs	Semaglutide can slow your digestion, and it may take longer for your body to absorb any medicines you take by mouth. Tell your doctor about all your other medicines, especially insulin or other diabetes medicines, such as dulaglutide, exenatide, liraglutide, Byetta, Trulicity, Victoza, and others. Other drugs may affect semaglutide, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use. Semaglutide drug interactions (more detail)
pregnancy and breastfeeding	Pregnancy: Men and women should stop using semaglutide at least 2 months before you plan to get pregnant. Ask your doctor for a safer medicine to use during this time. Controlling diabetes is very important during pregnancy, as is gaining the right amount of weight. Even if you are overweight, losing weight during pregnancy could harm the unborn baby. Breastfeeding: Ask a doctor if it is safe to breastfeed while using this Ozempic or Wegovy. You should not breastfeed while using Rybelsus.

Relevant Products

Apixaban
CAS：503612-47-3
Liraglutide
CAS：204656-20-2
Citicoline Sodium
CAS：33818-15-4